

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM827260

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
DIABETOMICS, INC.		05/15/2023	Corporation: OREGON
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Rogue Venture Partners Fund III, L.P., as collateral agent		
<b>Street Address:</b>	3002 Elm Creek Place		
<b>City:</b>	San Antonio		
<b>State/Country:</b>	TEXAS		
<b>Postal Code:</b>	78230		
<b>Entity Type:</b>	Limited Partnership: DELAWARE		
<b>PROPERTY NUMBERS Total: 4</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	97924951	GLUCEMA	
<b>Registration Number:</b>	6085943	INSUDEX	
<b>Registration Number:</b>	5601588	LUMELLA	
<b>Registration Number:</b>	4019794	DIABETOMICS	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2067577098		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	206-757-8098		
<b>Email:</b>	catherinemaxson@dwt.com,michaelamalone@dwt.com		
<b>Correspondent Name:</b>	Catherine E. Maxson		
<b>Address Line 1:</b>	920 Fifth Avenue, Suite 3300		
<b>Address Line 4:</b>	SEATTLE, WASHINGTON 98104		
<b>ATTORNEY DOCKET NUMBER:</b>	105844-20		
<b>NAME OF SUBMITTER:</b>	Catherine E. Maxson		
<b>SIGNATURE:</b>	/Catherine e Maxson/		
<b>DATE SIGNED:</b>	07/26/2023		
<b>Total Attachments: 14</b>			
source=IPSA May 2023 with Exhibits A and B#page1.tif			

CH \$115.00 97924951

source=IPSA May 2023 with Exhibits A and B#page2.tif  
source=IPSA May 2023 with Exhibits A and B#page3.tif  
source=IPSA May 2023 with Exhibits A and B#page4.tif  
source=IPSA May 2023 with Exhibits A and B#page5.tif  
source=IPSA May 2023 with Exhibits A and B#page6.tif  
source=IPSA May 2023 with Exhibits A and B#page7.tif  
source=IPSA May 2023 with Exhibits A and B#page8.tif  
source=IPSA May 2023 with Exhibits A and B#page9.tif  
source=IPSA May 2023 with Exhibits A and B#page10.tif  
source=IPSA May 2023 with Exhibits A and B#page11.tif  
source=IPSA May 2023 with Exhibits A and B#page12.tif  
source=IPSA May 2023 with Exhibits A and B#page13.tif  
source=IPSA May 2023 with Exhibits A and B#page14.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT, dated as of May 15, 2023, (this “**Agreement**”) is entered into among Rogue Venture Partners Fund III L.P. (“**Rogue**”), John Stirek (“**Stirek**”), an individual, Dudley Family Trust dated 9/9/1999, (“**Dudley Family Trust**”), Karl Rickard Miller Jr. Revocable Trust (“**KRM Trust**”), and any subsequent persons who become lender parties hereto pursuant to Section 8 below (together, the “**Lenders**” and, individually, each a “**Lender**”), Rogue, as collateral agent for the benefit of the Lenders (in such capacity, the “**Collateral Agent**”), and Diabetomics, Inc., an Oregon corporation (“**Grantor**”).

### RECITALS

WHEREAS, the Lenders have provided and may continue to provide certain loans to Grantor, and have agreed to modify the original terms of such loans, all as evidenced by (a) that certain Amended and Restated Promissory Note, dated as of the date hereof, made by Grantor to Rogue, in the principal amount of \$250,000, which amends and restates a Promissory Note previously made by Grantor to Rogue, dated December 12, 2022, (b) that certain Amended and Restated Promissory Note, dated as of the date hereof, made by Grantor to Rogue, in the principal amount of \$100,000, which amends and restates a Promissory Note previously made by Grantor to Rogue, dated January 24, 2023, (c) that certain Amended and Restated Promissory Note, dated as of the date hereof, made by Grantor to Stirek, in the principal amount of \$250,000, which amends and restates a Promissory Note previously made by Grantor to Stirek, dated February 8, 2023, (d) that certain Amended and Restated Promissory Note, dated as of the date hereof, made by Grantor to Dudley Family Trust, in the principal amount of \$75,000, which amends and restates a Promissory Note previously made by Grantor to Dudley Family Trust, dated March 22, 2023, and (e) that certain Amended and Restated Promissory Note, dated as of the date hereof, made by Grantor to KRM Trust, in the principal amount of \$75,000, which amends and restates a Promissory Note previously made by Grantor to KRM Trust, dated March 23, 2023 (f) that certain Amended and Restated Promissory Note, dated as of the date hereof, made by Grantor to Dudley Family Trust, in the principal amount of \$75,000, which amends and restates a Promissory Note previously made by Grantor to Dudley Family Trust, dated April 5, 2023, and (g) that certain Amended and Restated Promissory Note, dated as of the date hereof, made by Grantor to KRM Trust, in the principal amount of \$75,000, which amends and restates a Promissory Note previously made by Grantor to KRM Trust, dated April 10, 2023 (h) that certain Amended and Restated Promissory Note, dated as of the date hereof, made by Grantor to Dudley Family Trust, in the principal amount of \$50,000, which amends and restates a Promissory Note previously made by Grantor to Dudley Family Trust, dated April 21, 2023, and (i) that certain Amended and Restated Promissory Note, dated as of the date hereof, made by Grantor to KRM Trust, in the principal amount of \$50,000, which amends and restates a Promissory Note previously made by Grantor to KRM Trust, dated April 21, 2023 (j) that certain Amended and Restated Promissory Note, dated as of the date hereof, made by Grantor to Dudley Family Trust, in the principal amount of \$50,000, which amends and restates a Promissory Note previously made by Grantor to Dudley Family Trust, dated May 10, 2023, and (k) that certain Amended and Restated Promissory Note, dated as of the date hereof, made by Grantor to KRM Trust, in the principal amount of \$50,000, which amends and restates a Promissory Note previously made by Grantor to KRM Trust, dated May 10, 2023 (the foregoing Amended and Restated Promissory Notes, together with any Replacement Note as defined therein, collectively, the “**Notes**” and, individually, each a “**Note**”); and

WHEREAS, to induce the Lenders to accept the Notes and continue to extend credit to Grantor, and as security for the payment and performance of all Obligations (defined below), Grantor has agreed to enter into this Agreement and to grant to the Collateral Agent, for the benefit of the Lenders, a security interest in the Intellectual Property Collateral (defined below), on the terms and conditions set forth herein.

### AGREEMENT

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, Grantor hereby covenants and agrees as follows:

1. **Defined Terms.** Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Notes or, if not defined therein, the UCC. As used herein:

(a) “**Obligations**” means all debt, principal, interest, fees, expenses, liabilities, obligations and other amounts owed by Grantor to any Lender or the Collateral Agent under any Note or this Agreement, whether absolute or contingent, due or to become due, now existing or hereafter arising, including any amounts accruing after the commencement of any bankruptcy or insolvency proceeding and whether or not allowed or allowable as a claim in any such proceeding; and

(b) “**UCC**” means the Uniform Commercial Code as from time to time in effect in the State of Oregon; provided, if perfection or the effect of perfection or non-perfection or the priority of the security interest in any Intellectual Property Collateral is governed by the Uniform Commercial Code as in effect in a jurisdiction other than the State of Oregon, then “**UCC**” means the Uniform Commercial Code as in effect from time to time in such other jurisdiction for purposes of the provisions hereof relating to such perfection, effect of perfection or non-perfection or priority.

**2. Grant of Security Interest.** To secure the payment and performance in full of the Obligations, Grantor hereby grants to the Collateral Agent, for the benefit of the Lenders, a security interest in all right, title, and interest of Grantor in any and all of the following property of Grantor, whether now existing or hereafter acquired or created (collectively, the “**Intellectual Property Collateral**”):

(a) copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held (collectively, the “**Copyrights**”);

(b) trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks (collectively, the “**Trademarks**”), including the Trademarks listed on Exhibit A; *provided*, that Intellectual Property Collateral shall not include any United States intent-to-use trademark applications for which an amendment to allege use has not been submitted and accepted by the United States Patent and Trademark Office pursuant to 15 U.S.C. Section 1060(a) (or any successor provision); *provided, further*, that upon such acceptance, such intent-to-use trademark application shall automatically be considered Intellectual Property Collateral;

(c) patents, patent applications and like protections including without limitation improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same (collectively, the “**Patents**”), including the Patents listed on Exhibit B;

(d) mask work or similar rights available for the protection of semiconductor chips or other products (collectively, the “**Mask Works**”);

(e) trade secrets, source code, formulae, database rights, processes, technology and any and all other intellectual property rights in software and software products;

(f) design rights;

(g) claims for damages by way of past, present and future infringement of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works, and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) amendments, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) income, royalties, proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

The rights and remedies of the Collateral Agent with respect to the security interests granted hereunder are in addition to rights and remedies of the Lenders set forth in the Notes, and other rights and remedies which are now or hereafter available to the Collateral Agent or any Lender as a matter of law or equity. Each right, power and remedy of the Collateral Agent or any Lender provided for herein or in the Notes, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein, and the exercise by the Collateral Agent or any Lender of any one or more of such rights, powers or remedies does not preclude the simultaneous or later exercise by the Collateral Agent or any Lender of any other rights, powers or remedies.

**3. Representations and Covenants of Grantor.**

(a) Grantor hereby represents and warrants that it is the true and lawful exclusive owner of the Intellectual Property Collateral (or, in the case of after-acquired or after-created Intellectual Property Collateral, will be the true and lawful exclusive owner of such Intellectual Property Collateral at the time of acquisition or creation), free and clear of any liens, leases, encumbrances, judgments or other claims.

(b) Until this Agreement is terminated pursuant to the terms hereof, Grantor will not (i) without the prior written consent of the Collateral Agent, sell, lease or otherwise dispose of the Intellectual Property Collateral (excluding, for the avoidance of doubt, any non-exclusive license of Intellectual Property Collateral entered into in the ordinary course of business), nor (ii) create, incur, or suffer to exist any lien, security interest or other encumbrance on the Intellectual Property Collateral except the security interest created under this Agreement.

(c) Grantor hereby agrees that, anything herein to the contrary notwithstanding, Grantor shall retain full and complete responsibility for the prosecution, defense, enforcement or any other necessary or desirable actions in connection with the Intellectual Property Collateral.

**4. Collateral Agent Provisions.**

(a) Each Lender hereby appoints Rogue as the Collateral Agent hereunder and authorizes the Collateral Agent to (i) execute and deliver this Agreement, (ii) take such other actions on its behalf and to exercise all rights, powers and remedies and perform the duties as are expressly delegated to the Collateral Agent by written agreement, including this Agreement and (iii) exercise such powers as are reasonably incidental thereto.

(b) Without limiting the generality of clause (a) above, the Collateral Agent shall have the sole and exclusive right and authority (to the exclusion of the Lenders), and is hereby authorized, to (i) act as collecting and disbursing agent for the Lenders with respect to all payments and collections arising from the Intellectual Property Collateral, (ii) file and prove claims and file other documents necessary or desirable to allow the claims of any Lender with respect to any of the Obligations in any bankruptcy, insolvency or similar proceeding (but not to vote, consent or otherwise act on behalf of such Lender), (iii) act as collateral agent for each Lender for purposes of the perfection of all liens and security interests created by this Agreement, (iv) manage, supervise and otherwise deal with the Intellectual Property Collateral, (v) take such other action as is necessary or desirable to maintain the perfection and priority of the liens and security interests created by purported to be created by this Agreement and (vi) exercise all remedies given to the Collateral Agent and the other Lenders with respect to Grantor or the Intellectual Property Collateral, whether under any Note, this Agreement, applicable law or otherwise.

(c) Under the Notes and this Agreement, the Collateral Agent (i) is acting solely on behalf of the Lenders with duties that are entirely administrative in nature, notwithstanding the use of the defined term "Collateral Agent", which term is used for title purposes only and (ii) is not assuming and shall not have any actual or implied obligations, functions, responsibilities, duties, under the Notes or this Agreement other than as expressly set forth therein or herein, nor any role as agent, fiduciary or trustee of or for any Lender or any other person or entity, and each Lender, by accepting the benefits of this Agreement, hereby waives and agrees not to assert any claim against the Collateral Agent based on the roles, duties and legal relationships expressly disclaimed in clauses (i) and (ii) above.

(d) Each Lender, by accepting the benefits of this Agreement, agrees that (i) any action taken (or omitted to be taken) by the Collateral Agent in accordance with the provisions of this Agreement, (ii) any action taken (or omitted to be taken) by the Collateral Agent in reliance upon the instructions of any Lender and (iii) the exercise by the Collateral Agent of the powers set forth herein, together with such other powers as are reasonably incidental thereto, shall be authorized and binding upon all of the Lenders.

(e) The Collateral Agent shall not be required to exercise any discretion or take, or to omit to take, any action, including with respect to enforcement or collection, except any action it is required to take or omit to take (i) under the terms of this Agreement or (ii) pursuant to written instruction from all Lenders.

(f) Notwithstanding any provision to the contrary in this Agreement or in any Note, any payment made by Grantor to any Lender in satisfaction of its obligations under any Note shall be divided and paid to each Lender in proportion to such Lender's pro rata share of the Obligations (determined in accordance with its percentage of the outstanding Obligations as of the time that such payment is received), and in the event any Lender receives more than such pro rata share, such Lender agrees to hold the excess in trust for the benefit of the other Lenders. Any payments made by Grantor to the Collateral Agent and, without duplication, any proceeds of the Intellectual Property Collateral received by the Collateral Agent, shall be promptly disbursed by the Collateral Agent to each Lender based on such Lender's pro rata share of the Obligations (determined in accordance with its percentage of the outstanding Obligations as of the time that such payments or proceeds are received).

5. **Collateral Agent Expenses.** Grantor shall, promptly upon demand by the Collateral Agent, indemnify and reimburse the Collateral Agent for any reasonable out-of-pocket fees, costs and expenses (including reasonable fees, charges and disbursements of financial, legal and other advisors to the Collateral Agent and any taxes paid in the name of, or on behalf of, Grantor) that may be incurred by the Collateral Agent or any of its agents or representatives in connection with the preparation, execution, delivery, administration, modification, consent, waiver or enforcement of, or the taking of any other action in respect of, or legal advice with respect to, its rights or responsibilities under, this Agreement or any Note. Without limiting the foregoing, if Grantor fails to perform any agreement contained herein, the Collateral Agent may itself perform, or cause the performance of, such agreement, and the reasonable out-of-pocket expenses of the Collateral Agent incurred in connection therewith shall be payable by Grantor.

6. **Governing Law.** THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAW OF THE STATE OF OREGON.

7. **Termination.** Upon the date on which the Obligations have been paid in full, the Intellectual Property Collateral shall be released from the security interest created hereby, and this Agreement and all obligations of Grantor, Lenders and the Collateral Agent shall terminate, all without delivery of any instrument or further action by any party, and all rights to the Intellectual Property Collateral shall revert to Grantor. On such date, each of Lenders and the Collateral Agent will, at the request of Grantor, execute and deliver to Grantor a proper instrument or instruments acknowledging the satisfaction and termination of this Agreement

8. **Additional Lender Parties.** Other persons who provide loans to Grantor after the date hereof on substantially the same terms as the Notes may become a party to this Agreement by executing and delivering a counterpart signature page hereto agreeing to be bound by and subject to the terms of this Agreement as a Lender hereunder; provided, however, that (a) if such person is not already a party to this Agreement, such person's designation as a Lender shall have been approved by the board of directors of Grantor and (b) if the aggregate principal amount outstanding under the Notes and all other loans to Grantor after the date hereof would exceed \$2,500,000, such person shall have been approved as a Lender by the Collateral Agent. Each such person shall thereafter be deemed a Lender and each promissory note issued by Grantor to such person shall be deemed a Note for all purposes under this Agreement.


9. **Counterparts.** This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument, and any of the parties hereto may execute this Agreement by signing any such counterpart. Delivery of an executed counterpart to this Agreement by facsimile transmission or by electronic mail (in PDF format) shall be as effective as delivery of a manually executed counterpart hereof.

*[Balance of Page Intentionally Left Blank]*

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

**GRANTOR:**

**DIABETOMICS, INC.**  
an Oregon corporation

By:  \_\_\_\_\_  
B1BBCF7F18764F6...

Name: Barbara Chiapuzio

Title: Chief Financial Officer




IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

**LENDER:**

**Rogue Venture Partners Fund III, LP.**


By: Rogue Venture Partners III, LLC, its General Partner

By:  \_\_\_\_\_  
18BBEE4DAC90455...  
Tom Sperry, Manager

**COLLATERAL AGENT:**

**Rogue Venture Partners Fund III, LP.**  
as Collateral Agent

By: Rogue Venture Partners III, LLC, its General Partner

By:  \_\_\_\_\_  
18BBEE4DAC90455...  
Tom Sperry, Manager

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.


**LENDER:**


DocuSigned by:  
*John Stirek*  
151AADEDE02249B...  
JOHN STIREK

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

**LENDER:**

**Dudley Family Trust Dated 9/9/1999**


DocuSigned by:  
By:  \_\_\_\_\_  
D36843EEFEC14E3...  
Chris G. Dudley, as co-trustee

DocuSigned by:  
By:  \_\_\_\_\_  
E740AACDFCD5412...  
Christine K. Dudley, as co-trustee

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

**LENDER:**

**Karl Rickard Miller Jr. Revocable Trust**

By:  \_\_\_\_\_  
5A699181A7D9450...  
K. Rickard Miller Jr.

**Exhibit A**

**Trademarks**

<b>Jurisdiction</b>	<b>Mark</b>	<b>Status</b>	<b>Application Date Registration Date Application # Registration #</b>	<b>Class</b>
<b>UNITED STATES</b>				
United States	GLUCEMA	Pending	App 08-MAY-2023 App 97924951	5 10
United States	INSUDEX	Registered	App 04-MAY-2016 Reg 23-JUN-2020 App 87024827 Reg 6085943	5 10
United States	LUMELLA	Registered	App 30-APR-2015 Reg 06-NOV-2018 App 86615859 Reg 5601588	5 10 44
United States	DIABETOMICS	Registered	App 07-JUL-2008 Reg 30-AUG-2011 App 77516001 Reg 4019794	5 10
<b>OUTSIDE THE UNITED STATES</b>				
Brazil	DIABETOMICS	Registered	App 07-JAN-2009 Reg 23-DEC-2014 App 830164022 Reg 830164022	5
WIPO - Extension to China of IRN 1287278	LUMELLA	Registered	Reg 30-OCT-2015 Reg 1287278  (based on U.S. App. Nos. 86615859	44
China	DIABETOMICS	Registered	App 07-JAN-2009 Reg 21-JUL-2010 App 7153578 Reg 7153578	10
European Union	GLUCEMA	Registered	App 20-MAY-2020 Reg 09-JUN-2020 App 18242231 Reg 18242231	5 10 42 44

Jurisdiction	Mark	Status	Application Date Registration Date Application # Registration #	Class
European Union	DIABETOMICS	Registered	App 04-DEC-2008 Reg 21-JUL-2009 App 7442023 Reg 7442023	5 10
WIPO - Extension to European Union of International Registration No. 1345466	INSUDEX	Registered	Reg 02-NOV-2016 Reg 1345466 (based on U.S. App. No. 87024827)	5 10 16
WIPO - Extension to European Union of IRN 1287278	LUMELLA	Registered	Reg 30-OCT-2015 Reg 1287278 (based on U.S. App. Nos. 86615859)	5 10 44
India	DIABETOMICS	Registered	App 05-DEC-2008 Reg 16-AUG-2017 App 1760971 Reg 1629488	5 10
WIPO - Extension to India of IRN 1499230 (IRDI No. 4356028)	GLUCEMA	Registered	Reg 30-JUL-2019 Reg 1499230 (based on U.S. App. No. 88508440)	5 10 42 44
WIPO - Extension to India of IRN 1287278 (IRDI No. 3318133)	LUMELLA	Registered	Reg 30-OCT-2015 Reg 1287278 (based on U.S. App. Nos. 86615859)	5 10 44
Russian Federation	DIABETOMICS	Registered	App 07-JUL-2008 Reg 15-JAN-2010 App 2008737712 Reg 398334	5 10
United Kingdom	GLUCEMA	Registered	App 20-MAY-2020 Reg 09-JUN-2020 App UK00918242231 Reg UK00918242231	5 10 42 44
United Kingdom	DIABETOMICS	Registered	App 04-DEC-2008 Reg 21-JUL-2009 App UK00907442023 Reg UK00907442023	5 10
United Kingdom	INSUDEX	Registered	App 02-NOV-2016 Reg 11-JUN-2018 App UK00801345466	5 10 16

Jurisdiction	Mark	Status	Application Date Registration Date Application # Registration #	Class
			Reg UK00801345466	
United Kingdom	LUMELLA	Registered	App 30-OCT-2015 Reg 13-DEC-2016 App UK00801287278 Reg UK00801287278	5 10 44

**Exhibit B**

**Patents**

Country	Application Date	Application No.	Registration Date	Registration No.	Title
US	Dec-05-2017	158033656	May-04-2021	10,986,228	BIOMARKERS FOR ASSESSMENT OF PREECLAMPSIA
HK	Jul-23-2015	17313690.9		NA	BIOMARKERS FOR ASSESSMENT OF PREECLAMPSIA
IN	Jul-23-2015	20171700653	Mar-13-2023	204026	BIOMARKERS FOR ASSESSMENT OF PREECLAMPSIA
PCT	Jul-23-2015	PCT/US2015/041786		NA	BIOMARKERS FOR ASSESSMENT OF PREECLAMPSIA
US	Mar-11-2013	13792,544	Oct-07-2014	8,852,873	MATERNAL BIOMARKERS FOR GESTATIONAL DIABETES
US	Oct-16-2014	14616,383	Jul-05-2016	8,369,370	MATERNAL BIOMARKERS FOR GESTATIONAL DIABETES
CN	Mar-11-2013	201360031224.2	May-24-2017	ZL201360031224.2	MATERNAL BIOMARKERS FOR GESTATIONAL DIABETES
US	Nov-21-2013	14085,974	Mar-10-2015	8,975,034	MATERNAL BIOMARKERS FOR GESTATIONAL DIABETES
DE	Mar-11-2013	13775210.1	May-09-2018	202013037286.9	MATERNAL BIOMARKERS FOR GESTATIONAL DIABETES
EP	Mar-11-2013	13775210.1	May-09-2018	2036845	MATERNAL BIOMARKERS FOR GESTATIONAL DIABETES
ES	Mar-11-2013	13775210.1	May-09-2018	2036845	MATERNAL BIOMARKERS FOR GESTATIONAL DIABETES
FR	Mar-11-2013	13775210.1	May-09-2018	2036845	MATERNAL BIOMARKERS FOR GESTATIONAL DIABETES
GB	Mar-11-2013	13775210.1	May-09-2018	2036845	MATERNAL BIOMARKERS FOR GESTATIONAL DIABETES
IN	Mar-11-2013	94103DELNF2014	Oct-24-2019	523591	MATERNAL BIOMARKERS FOR GESTATIONAL DIABETES
IT	Mar-11-2013	13775210.1	May-09-2018	500100000265681	MATERNAL BIOMARKERS FOR GESTATIONAL DIABETES
PCT	Mar-11-2013	PCT/US2013/030152		NA	MATERNAL BIOMARKERS FOR GESTATIONAL DIABETES
US	Jul-23-2009	13055,605	Jul-02-2013	8,476,006	METHODS FOR DETECTING PRE-DIABETES AND DIABETES
PCT	Jul-23-2009	PCT/US2009/051578		NA	METHODS FOR DETECTING PRE-DIABETES AND DIABETES
US	May-11-2010	12777,956	May-01-2012	8,168,336	METHODS FOR DETECTING PRE-DIABETES AND DIABETES USING DIFFERENTIAL PROTEIN GLYCOSYLATION
US	Apr-26-2012	13457,300	Jul-30-2013	8,497,076	METHODS FOR DETECTING PRE-DIABETES AND DIABETES USING DIFFERENTIAL PROTEIN GLYCOSYLATION
US	Apr-26-2012	13457,325	Sep-10-2013	8,530,175	METHODS FOR DETECTING PRE-DIABETES AND DIABETES USING DIFFERENTIAL PROTEIN GLYCOSYLATION
US	Apr-26-2012	13457,243	Jul-30-2013	8,497,077	METHODS FOR DETECTING PRE-DIABETES AND DIABETES USING DIFFERENTIAL PROTEIN GLYCOSYLATION
PCT	May-11-2010	PCT/US2010/034385		NA	METHODS FOR DETECTING PRE-DIABETES AND DIABETES USING DIFFERENTIAL PROTEIN GLYCOSYLATION
US	Mar-26-2014	14226,131	Jul-05-2016	8,383,382	SALIVARY PROTEIN GLYCOSYLATION TEST FOR DIAGNOSIS AND MONITORING OF DIABETES
CN	Mar-26-2015	201510138323.1	Aug-08-2017	ZL201510138323.1	SALIVARY PROTEIN GLYCOSYLATION TEST FOR DIAGNOSIS AND MONITORING OF DIABETES
DE	Mar-25-2015	15160916.1	May-09-2018	202015010852.3	SALIVARY PROTEIN GLYCOSYLATION TEST FOR DIAGNOSIS AND MONITORING OF DIABETES
EP	Mar-25-2015	15160916.1	May-09-2018	2924436	SALIVARY PROTEIN GLYCOSYLATION TEST FOR DIAGNOSIS AND MONITORING OF DIABETES
ES	Mar-25-2015	15160916.1	May-09-2018	2924436	SALIVARY PROTEIN GLYCOSYLATION TEST FOR DIAGNOSIS AND MONITORING OF DIABETES
FR	Mar-25-2015	15160916.1	May-09-2018	2924436	SALIVARY PROTEIN GLYCOSYLATION TEST FOR DIAGNOSIS AND MONITORING OF DIABETES
IT	Mar-25-2015	15160916.1	May-09-2018	202015010852.3	SALIVARY PROTEIN GLYCOSYLATION TEST FOR DIAGNOSIS AND MONITORING OF DIABETES
GB	Mar-25-2015	15160916.1	May-09-2018	2924436	SALIVARY PROTEIN GLYCOSYLATION TEST FOR DIAGNOSIS AND MONITORING OF DIABETES

119027112.3 0044784-00001